Frontiers in pharmacology · 2026
Fcγ receptor expression on monocytes and association with etanercept efficacy in rheumatoid arthritis: a prospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Tongxin, Li Hanchao, Zhu Li, Pan Ying, Luo Jing, Zhang Jing, Hu Nan, He Lan, Sun Yining
Аннотация
BACKGROUND: To investigate whether Fcγ receptors (FcγRs) expression on peripheral blood monocytes predicts clinical response to etanercept in rheumatoid arthritis (RA).
METHODS: In this prospective cohort study, FcγRs expression on peripheral blood monocyte subsets was analyzed by flow cytometry. The primary outcome was the change in DAS28-CRP from baseline to week 12. The secondary outcome was the change in DAS28-ESR.
RESULTS: Following etanercept therapy, the proportion of FcγRI-positive monocytes and classical (CD14++CD16-) monocytes was reduced, while the proportion of non-classical (CD14+CD16++) monocytes was increased. Changes in intermediate monocytes (CD14++CD16+) were positively correlated with both DAS28-CRP change and DAS28-ESR change at week 24 after etanercept therapy. Patients with high intermediate (CD14++CD16+) monocytes showed significantly greater reductions in DAS28-CRP at week 12.
CONCLUSION: Intermediate monocytes (CD14++CD16+) were correlated with improvements in DAS28-CRP achieved by week 12 following etanercept therapy. RA patients with low intermediate monocytes may derive less benefit from etanercept treatment.
METHODS: In this prospective cohort study, FcγRs expression on peripheral blood monocyte subsets was analyzed by flow cytometry. The primary outcome was the change in DAS28-CRP from baseline to week 12. The secondary outcome was the change in DAS28-ESR.
RESULTS: Following etanercept therapy, the proportion of FcγRI-positive monocytes and classical (CD14++CD16-) monocytes was reduced, while the proportion of non-classical (CD14+CD16++) monocytes was increased. Changes in intermediate monocytes (CD14++CD16+) were positively correlated with both DAS28-CRP change and DAS28-ESR change at week 24 after etanercept therapy. Patients with high intermediate (CD14++CD16+) monocytes showed significantly greater reductions in DAS28-CRP at week 12.
CONCLUSION: Intermediate monocytes (CD14++CD16+) were correlated with improvements in DAS28-CRP achieved by week 12 following etanercept therapy. RA patients with low intermediate monocytes may derive less benefit from etanercept treatment.